Priya Dayananth
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)United States Military Academy(US)Quantitative BioSciences(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Synthesis and biological activity, Computational Drug Discovery Methods, Cancer-related Molecular Pathways, Cancer Mechanisms and Therapy
Most-Cited Works
- → A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1(1994)6,075 cited
- → Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors(2013)676 cited
- → A candidate prostate cancer susceptibility gene at chromosome 17p(2001)555 cited
- Complex structure and regulation of the P16 (MTS1) locus.(1995)
- → Characterization of a carboxy-terminal BRCA1 interacting protein(1998)164 cited
- → Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors(2018)146 cited
- Genomic structure, expression and mutational analysis of the P15 (MTS2) gene.(1995)
- Reversible, p16-mediated cell cycle arrest as protection from chemotherapy.(1996)